123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: A systematic review and meta-analysis

Parkinsonism and Related Disorders

Volumn 18, Issue 5, 2012, Pages 494-500

  Orimo, Satoshi ^a   Suzuki, Masahiko ^b   Inaba, Akira ^a   Mizusawa, Hidehiro ^c  

^a The Mutualaid Association of Public School Teachers)   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Differential diagnosis; Meta analysis; MIBG myocardial scintigraphy; Neurodegenerative parkinsonism; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; CONFIDENCE INTERVAL; CORTICOBASAL DEGENERATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HEART TO MEDIASTINUM RATIO; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; META ANALYSIS; MYOCARDIAL PERFUSION IMAGING; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SYSTEMATIC REVIEW; DEGENERATIVE DISEASE; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84862777562     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.01.009     Document Type: Article

References (31)

1. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998, 155:60-67.
2. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999, 67:189-194.
3. 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001, 70:781-783.
4. Orimo S., Amino T., Itoh Y., Takahashi A., Kojo T., Uchihara T., et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005, 109:583-588.
5. Amino T., Orimo S., Itoh Y., Takahashi A., Uchihara T., Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 2005, 15:29-34.
6. Reitsma J.B., Glas A.S., Rutjes A.W., Scholten R.J., Bossuyt P.M., Zwinderman A.H. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005, 58:982-990.
7. Menke J. Bivariate random-effects meta-analysis of sensitivity and specificity with SAS PROC GLIMMIX. Methods Inf Med 2010, 49:54-64.
8. Takatsu H., Nagashima K., Murase M., Fujiwara H., Nishida H., Matsuo H., et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000, 284:44-45.
9. Reinhardt M.J., Jungling F.D., Krause T.M., Braune S. Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 2000, 27:595-600.
10. Taki J., Nakajima K., Hwang E.H., Matsunari I., Komai K., Yoshita M., et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000, 27:566-573.
11. Courbon F., Brefel-Courbon C., Thalamas C., Alibelli M.J., Berry I., Montastruc J.L., et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003, 18:890-897.
12. Nagayama H., Hamamoto M., Ueda M., Nagashima J., Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005, 76:249-251.
13. 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 2006, 47:1099-1101.
14. Shin D.H., Lee P.H., Bang O.Y., Joo I.S., Huh K. Clinical implications of cardiac-MIBG SPECT in the differentiation of parkinsonian syndromes. J Clin Neurol 2006, 2:51-57.
15. Köllensperger M., Seppi K., Liener C., Boesch S., Heute D., Mair K.J., et al. Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 2007, 22:1771-1776.
16. Fröhlich I., Pilloy W., Vaillant M., Diederich N.J. Myocardial MIBG scintigraphy: a useful clinical tool?: a retrospective study in 50 parkinsonian patients. Neurol Sci 2010, 31:403-406.
17. Tateno F., Sakakibara R., Kishi M., Ogawa E., Terada H., Ogata T., et al. Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic. Parkinsonism Relat Disord 2011, 17:395-397.
18. Südmeyer M., Antke C., Zizek T., Beu M., Nikolaus S., Wojtecki L., et al. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med 2011, 52:733-740.
19. 123I-MIBG cardiac scintigraphy for the diagnosis of lewy body-related disorders. Mov Disord 2011, 26:1218-1224.
20. Treglia G., Cason E., Stefanelli A., Cocciolillo F., Di Giuda D., Fagioli G., et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res 27 July 2011, published online. 10.1007/s10286-011-0135-5.
21. Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125:861-870.
22. Orimo S., Ozawa E., Oka T., Nakade S., Tsuchiya K., Yoshimoto M., et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 2001, 57:1140-1141.
23. Orimo S., Oka T., Miura H., Tsuchiya K., Mori F., Wakabayashi K., et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002, 73:776-777.
24. 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci 2006, 243:101-104.
25. Fujishiro H., Frigerio R., Burnett M., Klos K.J., Josephs K.A., Delledonne A., et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 2008, 23:1085-1092.
26. Ghebremedhin E., Del Tredici K., Langston J.W., Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol 2009, 118:777-784.
27. Dickson D.W., Fujishiro H., DelleDonne A., Menke J., Ahmed Z., Klos K.J., et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008, 115:437-444.
28. Orimo S., Takahashi A., Uchihara T., Mori F., Kakita A., Wakabayashi K., et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007, 17:24-30.
29. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001, 11:351-355.
30. Orimo S., Kanazawa T., Nakamura A., Uchihara T., Mori F., Kakita A., et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 2007, 113:81-86.
31. Nagayama H., Yamazaki M., Ueda M., Nishiyama Y., Hamamoto M., Katayama Y., et al. Low myocardial MIBG uptake in multiple system atrophy with incidental Lewy body pathology: an autopsy case report. Mov Disord 2008, 23:1055-1057.